共 142 条
[1]
Forster M(2019)Managing risks with immune therapies in multiple sclerosis Drug Saf 42 633-47
[2]
Kury P(2011)Monoclonal antibody therapy-associated neurological disorders Nat Rev Neurol 7 165-72
[3]
Aktas O(2006)Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action Am J Transplant 6 859-66
[4]
Warnke C(2018)Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis JAMA Neurol 75 320-7
[5]
Havla J(2014)Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients Arthritis Res Ther 16 R80-41
[6]
Hohlfeld R(2014)Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients J Autoimmun 50 135-85
[7]
Bosch X(2018)Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland PLoS ONE 13 e0197415-7
[8]
Saiz A(2020)efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study Eur J Neurol 27 2277-8
[9]
Ramos-Casals M(2018)Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study J Neurol 265 1690-45
[10]
Group BS(2016)Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis JAMA Neurol 73 1342-93